Editing Openai/693cca0d-8c24-800e-bde2-ffa4c902003d (section)

=== Important caveats — be honest about cannabis limits & harms ===

• Most human neuroprotection data for cannabinoids is preliminary. Many cannabinoid neuroprotection results are from animal or cell studies; good human trials for long-term neuroprotection (preventing dementia, reversing ageing) are still limited. We need more large, long follow-ups. PMC<ref>{{cite web|title=PMC|url=https://pmc.ncbi.nlm.nih.gov/articles/PMC9932048/|publisher=pmc.ncbi.nlm.nih.gov|access-date=2025-12-13}}</ref>
• Cannabis isn’t harmless — dose, age and form matter. Heavy, long-term or adolescent cannabis use has been associated with cognitive changes, lower mid-life IQ in some cohorts and an elevated risk of psychotic disorders in vulnerable individuals; high-THC products increase some risks. Those are real harms to weigh. Moffitt & Caspi<ref>{{cite web|title=Moffitt & Caspi|url=https://moffittcaspi.trinity.duke.edu/sites/moffittcaspi.trinity.duke.edu/files/publication-uploads/Meier%20et%20al.%20AJP%20March%202022.pdf|publisher=Moffitt & Caspi|access-date=2025-12-13}}</ref>
• Regulation & product variability. Street or unregulated products have unpredictable potency, contaminants, or solvents. Medical-grade 1:1 oils (or pharmaceutically produced nabiximols where available) are much safer from a dosing/contaminant perspective. Dove Medical Press<ref>{{cite web|title=Dove Medical Press|url=https://www.dovepress.com/a-review-of-scientific-evidence-for-thccbd-oromucosal-spray-nabiximols-peer-reviewed-fulltext-article-JPR|publisher=Dove Medical Press|access-date=2025-12-13}}</ref>